LifeSciences BC > Uncategorized > viDA Therapeutics Announces Upcoming Participation at BioCentury’s Future Leaders in the Biotech Industry and Redefining Early Stage Investments Conferences

Print Friendly, PDF & Email

viDA Therapeutics Announces Upcoming Participation at BioCentury’s Future Leaders in the Biotech Industry and Redefining Early Stage Investments Conferences

March 17, 2014 – viDA Therapeutics

Vancouver, British Columbia (CNW – March 17, 2014) viDA Therapeutics Inc. (viDA), a private biotechnology company, today announced that it will present at two upcoming investor conferences. viDA has been selected as a Next Wave presenter at BioCentury’s “Future Leaders in the Biotech Industry” conference, to be held March 28, 2014, in New York City at 2:40 pm at the Millennium Broadway Hotel & Conference Center, New York City viDA will also present at Life Science Nation’s “Redefining Early Stage Investments” conference, to be held March 24, 2014, in Boston.

Alistair Duncan, President & Chief Executive Officer, will provide an overview of the Company’s business including the company’s first in class GzmB inhibitor program in tissue repair during his live presentations and will be available to participate in one-on-one meetings with investors who are registered to attend the conferences.

About viDA Therapeutics
viDA Therapeutics, Inc. (viDA) is a platform-based, biotechnology company developing first-in-class therapeutics based on its recent discovery of a new mechanism of action for a well-characterized protease target, Granzyme B (GzmB). This emerging science is leading to new treatments in impaired tissue repair, fibrosis, inflammation and aging and is pivotal in understanding the underlying causes of diseases affecting vasculature, skin, musculoskeletal and potentially neurological systems. GzmB, one of a family of five serine proteases known as granzymes, is now emerging as a key target for drug development given recent discoveries of its extracellular actions, providing a clear distinction from GzmB’s intracellular role in apoptosis. viDA is developing a library of granzyme inhibitors designed for multiple routes of administration to treat chronic and orphan skin conditions, fibrosis, autoimmune and cardiovascular disease. For more information, please visit www.vidatherapeutics.com.

Contact Info:
Alistair Duncan, President & CEO
viDA Therapeutics Inc.
Tel: 778-373-0916 or info@vidatherapeutics.com